Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.

ABSTRACT:

Background

Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin-remodelling complexes subunits. Although initial evaluations of the potential of BRD9-based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported.

Methods

We used various bioinformatics tools to generate a comprehensive, pan-cancer analyses of BRD9 expression in multiple dis

SUBMITTER: Chen Y 

PROVIDER: S-EPMC10835192 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature